Empowered Patient Podcast

Dr. Jay Venkatesan, CEO, Angion, a clinical stage biopharmaceutical company, discusses the company's work in organ self-repair and their initial focus in the nephrology space.  The company's lead candidate ANG-3777 is a small molecule that mimics a protein to stimulate this self-repair and regeneration following injury. Angion's therapeutic programs modulate the natural repair pathways of the body to fill unmet medical needs across many indications, including acute kidney injury, kidney transplantation, and chronic kidney disease. #organinjury  #organtransplant  #acutekidneyinjury #chronickidneydisease Angion

William Annett, CEO, OncoCyte discusses the exciting work the company is doing in the liquid biopsy space.  They have developed DetermaVu™ a liquid biopsy test for lung cancer, which studies show has the potential to detect the absence of cancer by analyzing a simple blood sample.  This technique allows individuals to potentially avoid risky, expensive lung biopsies.  The company recently announced promising R&D validation data and is planning to make the test available to patients and physicians later this year. @OncocyteLbx #LiquidBiopsy  #LungCancer #DetermaVu OncoCyte.com

Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD Abivax.com

Anna Landre is a Georgetown University sophomore who has a rare disease, spinal muscular atrophy (SMA) and is a wheelchair user.  In addition to being a full time student, Anna serves as Commissioner of the Advisory Neighborhood Commission where she advocates for people with disabilities and to improve accessibility on the Georgetown campus and in the district.  She talks about educating elected officials about possible ways to overcome challenges for those in wheelchairs and raising awareness about those living with rare diseases. #onestepaway  #SMA  #cureSMA  

Graham Kelly, CEO, Noxopharm discusses the company's lead clinical asset, Veyonda, a first-in-class chemotherapy and radiation enhancer that has immuno-oncology properties.  Veyonda has potential utility across solid tumors and boosts the effect of radiation therapy 2-3x in cancer cells.  It has already shown positive results in patients with metastatic castrate-resistant prostate cancer. #oncology #prostatecancer  #radiation #chemotherapy @Noxopharm Noxopharm

Jani Tuomi, Co-Founder, imaware and Kelly O'Neill, author and rheumatoid arthritis warrior talk about how at-home blood testing can empower patients with vital information to inform their discussions with doctors.  Both talk about how easy self testing for rheumatoid arthritis is a smart way to follow up on early warning signs of this often undiagnosed disease.   #rheumatoidarthritis @imaware_health @rawarrior imaware.health Rheumatoid Arthritis Unmasked: 10 Dangers of Rheumatoid Disease

Frank Ochberg MD is a psychiatrist, pioneer in trauma science, and co-founder of the Trust for Trauma Journalism, an organization with the goal of providing funding to advance exemplary reporting and the care of journalists who are bearing witness to violence, conflict and tragedy.  We talk about journalists as first responders, recognizing and treating their PTSD, and how all of us process trauma. #PTSD Trust for Trauma Journalism

Dr. Dan Alkon, President and Chief Scientific Officer, Neurotrope is an internationally recognized pioneer in research on brain based neural networks, the molecular basis of memory and degenerative brain disorders.  Neurotrope has seen very promising results in clinical trials with Bryostatin-1 with patients with advanced Alzheimer's disease, in many cases reversing the damage done to synapses and improving memory. They are on the path to attacking the progression of Alzheimer's and not just treating the symptoms. #neurotrope  #alzheimersdisease  #alzheimers #biotechnology  #biotech  #pharma @Neurotrope1 Neurotrope.com

Bob Geho, CEO, Diasome discusses the current treatments for diabetes and the nearly 100 year history of insulin.  He talks about the company's hepatocyte directed vesicle (HDV) nanotechnology that can be added to any insulin to lessen the instances of high and low blood sugar levels in people with diabetes.  HDV nanotechnology can be added to any insulin to improve its safety and efficacy by targeting specific organs and in this case, restoring the liver's natural role in blood glucose control. #Type1Diabetes  #Type2Diabetes  #Diabetes #Insulin @diasome Diasome.com

Brad Younggren MD, Chief Medical Officer, 98point was trained as an emergency medicine doctor and has brought his expertise to the online world of on-demand primary care.  Brad talks about the value of giving patients access to accurate resources at any time of the day to diagnose symptoms, recommend treatment, escalate to other medical professionals, and help manage chronic conditions.  Using a mobile app and artificial intelligence along with real primary care doctors, 98point is encouraging patients of all ages to take more direct control of their own health. @98point6inc 98Point6.com